ATE183087T1 - Verwendung von beta-hydroxy-beta- methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschen - Google Patents
Verwendung von beta-hydroxy-beta- methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschenInfo
- Publication number
- ATE183087T1 ATE183087T1 AT94903563T AT94903563T ATE183087T1 AT E183087 T1 ATE183087 T1 AT E183087T1 AT 94903563 T AT94903563 T AT 94903563T AT 94903563 T AT94903563 T AT 94903563T AT E183087 T1 ATE183087 T1 AT E183087T1
- Authority
- AT
- Austria
- Prior art keywords
- beta
- hydroxy
- hmb
- humans
- nitrogen retention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/996,187 US5348979A (en) | 1992-12-23 | 1992-12-23 | Method of promoting nitrogen retention in humans |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE183087T1 true ATE183087T1 (de) | 1999-08-15 |
Family
ID=25542600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT94903563T ATE183087T1 (de) | 1992-12-23 | 1993-12-09 | Verwendung von beta-hydroxy-beta- methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschen |
Country Status (9)
Country | Link |
---|---|
US (1) | US5348979A (de) |
EP (1) | EP0637239B1 (de) |
JP (1) | JP2925326B2 (de) |
AT (1) | ATE183087T1 (de) |
AU (1) | AU664511B2 (de) |
CA (1) | CA2129541C (de) |
DE (1) | DE69325998T2 (de) |
ES (1) | ES2134340T3 (de) |
WO (1) | WO1994014429A1 (de) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5597843A (en) * | 1995-06-07 | 1997-01-28 | Houghten Pharmaceuticals | Use of a substituted 1,3-benzodioxole to reduce a wasting condition |
US5756469A (en) * | 1996-07-26 | 1998-05-26 | Beale; Paxton K. | Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal |
US5716926A (en) * | 1996-07-26 | 1998-02-10 | Paxton K. Beale | Composition of pyruvate and protein and method for increasing protein concentration in a mammal |
US6323237B1 (en) | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
US6316038B1 (en) | 1997-03-17 | 2001-11-13 | Btg International Limited | Therapeutic compositions |
US20090253781A1 (en) * | 2002-05-24 | 2009-10-08 | Btg International Limited | Therapeutic compositions |
US6103764A (en) * | 1997-11-07 | 2000-08-15 | Iowa State University Research Foundation, Inc. | Method for increasing the aerobic capacity of muscle |
US6031000A (en) * | 1998-06-23 | 2000-02-29 | Iowa State University Research Foundation, Inc. | Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use |
AU2620600A (en) * | 1999-01-21 | 2000-08-07 | Steroidogenesis Inhibitors International | Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human |
EP1399138B1 (de) * | 2001-05-18 | 2006-02-08 | Lonza Ag | Verfahren zur herstellung fester formulierungen von natrium-3-hydroxy-3-methylbutyrat |
US20040048925A1 (en) * | 2002-09-09 | 2004-03-11 | Wiley David B. | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives |
US20040106678A1 (en) * | 2002-09-17 | 2004-06-03 | Dobbins Thomas A | Compositions for the parenteral administration of calcium and magnesium |
US6812249B2 (en) * | 2003-03-04 | 2004-11-02 | Sal Abraham | Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use |
US20050215640A1 (en) * | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
GB0420856D0 (en) * | 2004-09-20 | 2004-10-20 | Ketocytonyx Inc | Cns modulators |
WO2006020137A2 (en) | 2004-07-16 | 2006-02-23 | Ketocytonyx Inc. | Oligomeric compounds |
WO2006020179A2 (en) * | 2004-07-20 | 2006-02-23 | Ketocytonyx Inc. | Oligomeric ketone compounds |
WO2006012490A2 (en) * | 2004-07-23 | 2006-02-02 | Ketocytonyx Inc. | Ketogenic saccharides |
WO2006034361A2 (en) * | 2004-09-21 | 2006-03-30 | Ketocytonyx Inc. | Dopaminergic mimetics |
EP1793813A4 (de) * | 2004-09-21 | 2011-05-18 | Btg Int Ltd | Behandlung von adhd |
WO2007056176A2 (en) * | 2005-11-03 | 2007-05-18 | Southwest Immunology, Inc. | Compositions for preventing and reducing delayed onset muscle soreness |
RU2469719C2 (ru) | 2005-12-19 | 2012-12-20 | Абботт Лаборэтриз | СПОСОБ ЛЕЧЕНИЯ АЛЛЕРГИИ, СПОСОБ ЛЕЧЕНИЯ АСТМЫ, СПОСОБ СНИЖЕНИЯ РИСКА РАЗВИТИЯ ИНФЕКЦИИ И СПОСОБ ЛЕЧЕНИЯ СОСТОЯНИЯ, ХАРАКТЕРИЗУЮЩЕГОСЯ ДИСБАЛАНСОМ СОДЕРЖАНИЯ ЦИТОКИНОВ ТИПОВ 1 И 2, ПОСРЕДСТВОМ β-ГИДРОКСИ-β-МЕТИЛБУТИРАТА |
HUE039841T2 (hu) | 2008-12-09 | 2019-02-28 | Metabolic Tech Inc | Táplálkozási beavatkozás izomfunkció és erõ növeléséhez |
US9539224B2 (en) | 2008-12-09 | 2017-01-10 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
US9770424B2 (en) | 2008-12-09 | 2017-09-26 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
US9707241B2 (en) | 2008-12-09 | 2017-07-18 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
US9259430B2 (en) | 2008-12-09 | 2016-02-16 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
US11173167B2 (en) | 2008-12-09 | 2021-11-16 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
ES2608483T3 (es) * | 2009-12-18 | 2017-04-11 | Metabolic Technologies, Inc. | Método mejorado de administración de beta-hidroxi-beta-metilbutirato (HMB) |
EP2528459B1 (de) | 2010-01-29 | 2014-06-11 | Abbott Laboratories | Nährstoffemulsionen mit calcium-hmb |
US9693577B2 (en) | 2010-01-29 | 2017-07-04 | Abbott Laboratories | Method of preparing a nutritional powder comprising spray dried HMB |
CA2785523A1 (en) | 2010-01-29 | 2011-08-04 | Abbott Laboratories | Aseptically packaged nutritional liquids comprising hmb |
TWI526161B (zh) * | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣hmb及可溶性蛋白質之實質上透明營養液 |
CA2884405C (en) | 2012-09-10 | 2021-03-30 | Metabolic Technologies, Inc. | Composition of hmb and atp and methods of use |
US20150057346A1 (en) * | 2013-08-23 | 2015-02-26 | Abbott Laboratories | Methods of maintaining intramuscular myoglobin levels, maintaining maximal aerobic capacity, and enhancing the oxidative capacity of muscle in a subject |
AU2016323779B2 (en) | 2015-09-16 | 2022-03-17 | Metabolic Technologies, Inc. | Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma |
EP3405262A4 (de) | 2016-01-21 | 2019-08-28 | Metabolic Technologies, Inc. | Zusammensetzungen und verfahren zur verwendung von beta-hydroxy-beta-methylbutyrat (hmb) zur modulation von autophagie und lipophagie |
EP3528801A4 (de) | 2016-10-21 | 2020-07-15 | Metabolic Technologies, Inc. | Zusammensetzungen und verfahren zur verwendung von beta-hydroxy-beta-methylbutyrat (hmb) und probiotika |
JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
SG11202001142VA (en) | 2017-08-14 | 2020-03-30 | Axcella Health Inc | Amino acid compositions for the treatment of liver disease |
MA52971A (fr) | 2018-06-20 | 2021-04-28 | Axcella Health Inc | Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle |
JP7202800B2 (ja) * | 2018-07-13 | 2023-01-12 | ライオン株式会社 | 水分散性組成物、食品組成物、水分散液及び泡立ち抑制方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4100161A (en) * | 1974-04-15 | 1978-07-11 | The Johns Hopkins University | Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids |
JPS51104039A (de) * | 1975-03-07 | 1976-09-14 | Sankyo Kasei Kogyo Kk | |
US4677121A (en) * | 1985-01-22 | 1987-06-30 | The Johns Hopkins University | Method of inhibiting muscle protein degradation |
US4764531A (en) * | 1986-03-11 | 1988-08-16 | Iowa State University Research Foundation, Inc. | Method of feeding ketoisocaproate to laying chickens |
US4760090A (en) * | 1986-03-11 | 1988-07-26 | Iowa State University Research Foundation, Inc. | Method of feeding ketoisocaproate to cattle and sheep |
SE8803144L (sv) * | 1988-09-07 | 1990-03-08 | Kabivitrum Ab | Energisubstrat |
DE3943424A1 (de) * | 1989-12-30 | 1991-07-04 | Nephro Medica Pharma | Infusions- und injektionsloesung zur intravenoesen verabreichung |
US5028440A (en) * | 1990-01-30 | 1991-07-02 | Iowa State University Research Foundation, Inc. | Method of raising meat producing animals to increase lean tissue development |
US5087472A (en) * | 1990-01-30 | 1992-02-11 | Iowa State University Research Foundation, Inc. | Feed compositions for domestics animals containing hydroxymethylbutyrate |
US4992470A (en) * | 1990-02-08 | 1991-02-12 | Iowa State University Research Foundation, Inc. | Method of enhancing immune response of mammals |
US5097472A (en) * | 1990-02-22 | 1992-03-17 | Chenausky Peter P | Preionized transversely excited laser |
-
1992
- 1992-12-23 US US07/996,187 patent/US5348979A/en not_active Expired - Lifetime
-
1993
- 1993-12-09 DE DE69325998T patent/DE69325998T2/de not_active Expired - Lifetime
- 1993-12-09 WO PCT/US1993/011993 patent/WO1994014429A1/en active IP Right Grant
- 1993-12-09 JP JP6515213A patent/JP2925326B2/ja not_active Expired - Lifetime
- 1993-12-09 AT AT94903563T patent/ATE183087T1/de active
- 1993-12-09 ES ES94903563T patent/ES2134340T3/es not_active Expired - Lifetime
- 1993-12-09 EP EP94903563A patent/EP0637239B1/de not_active Expired - Lifetime
- 1993-12-09 CA CA002129541A patent/CA2129541C/en not_active Expired - Lifetime
- 1993-12-09 AU AU57463/94A patent/AU664511B2/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
JPH07507569A (ja) | 1995-08-24 |
CA2129541C (en) | 1999-05-11 |
DE69325998D1 (de) | 1999-09-16 |
EP0637239A1 (de) | 1995-02-08 |
CA2129541A1 (en) | 1994-07-07 |
AU664511B2 (en) | 1995-11-16 |
US5348979A (en) | 1994-09-20 |
EP0637239A4 (de) | 1996-12-04 |
AU5746394A (en) | 1994-07-19 |
WO1994014429A1 (en) | 1994-07-07 |
DE69325998T2 (de) | 2000-01-05 |
ES2134340T3 (es) | 1999-10-01 |
JP2925326B2 (ja) | 1999-07-28 |
EP0637239B1 (de) | 1999-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE183087T1 (de) | Verwendung von beta-hydroxy-beta- methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschen | |
CA2142314A1 (en) | Method of Reducing Blood Levels of Total Cholesterol and Low-Density Lipoprotein Cholesterol | |
ATE158182T1 (de) | Arzneimittel sowie deren herstellung und deren verwendung bei der bekämpfung von schmerzen und/oder entzündungen an tieren und menschen | |
BR9811825A (pt) | Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue | |
DE69333321D1 (de) | Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten. | |
DK0850068T3 (da) | Lipidekstrakt med antiinflammatorisk aktivitet | |
ATE81984T1 (de) | Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten. | |
DE60115432D1 (de) | Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen | |
KR950031063A (ko) | 프라바스타틴을 이용하여 관상 동맥 아테롬성 동맥경화증의 진행 속도를 감소시키는 방법 | |
Verbov | Cutaneous polyarteritis nodosa in a young child. | |
ATE94763T1 (de) | Medikament zur behandlung von fibrotischer stoerung und antifibrotische verbindung. | |
ATE288772T1 (de) | Sicherheitsmechanismus zum vorbeugen von unbeabsichtigter patienteninjektion sowie methode | |
DE3575671D1 (de) | Verwendung von saccharomyces-hefen fuer die herstellung eines arzneimittels gegen amoebiasis. | |
TWI263502B (en) | Pharmaceutical preparation for treating ischemic disease of heart or limbs | |
Noble | Failure of cefotaxime in the treatment of Yersinia enterocolitica sepsis despite in vitro susceptibility. | |
Robinson et al. | Autoimmune hypothyroidism in a patient with generalized resistance to thyroid hormone | |
EP0880967A3 (de) | Nephroprotektive Arzneimittel | |
Cherng et al. | Acute aphesia following tourniquet release in intravenous regional anesthesia with 0.75% lidocaine | |
ATE83931T1 (de) | Methode fuer die behandlung von viraler gehirnentzuendung. | |
ATE40795T1 (de) | Verwendung eines zerebral und peripher wirkenden antihypoxidotikums. | |
Patterson et al. | Psychosexual study of patients and non-patient homosexual groups. | |
Coma-Canella et al. | Haemodynamic effects of nifedipine, nitroglycerine and prazosin in pulmonary hypertension following ingestion of toxic oil | |
Johnson et al. | Special Considerations in the Elderly Prosthodontic Patient. | |
ES8500055A1 (es) | Procedimiento para la obtencion de un medicamento a base de un derivado de pirazolinona. | |
Greene et al. | The effect of age on ranitidine pharmacokinetics. |